Allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASCs) in a lung transplantation trial

Lung transplantation is the ultimate treatment of patients with severe lung disease. However, the short- and long-term prognosis is still problematic due to immunological reactions towards the transplanted lung.

The first patient has successfully been enrolled in the Chronic Lung Allograft dysfunction (Lung transplant rejection) phase I-II trial. The patients are randomized to a blinded treatment with intravenous infusion of either 100 million ASCs, 200 million ASCs or saline. A total of seven of the planned 30 patients have been enrolled without safety implications.